Addiction Medicine Fellowship

• London KS, Durney P, Warrick-Stone T, et al. “Decreased Effectiveness of a Novel Opioid Withdrawal Protocol Following the Emergence of Medetomidine as a Fentanyl Adulterant.” BioMed. 2025.
• Huo S, London K, Murphy L, Casey E, Durney P, et al. “Suspected Medetomidine Withdrawal Syndrome Among Fentanyl-Exposed Patients–Philadelphia, Pennsylvania, September 2024-January 2025.” MMWR. 2025.
• London KS, Huo S, Murphy L, Warrick-Stone T, Goodstein D, Montesi M, Carter M, Butt S, Alexander K, Satz W, Tasillo A, Xu L, Arora M, Casey E, McKeever R, Lowenstein M, Durney P, Hart B, Perrone J. Severe Fentanyl Withdrawal Associated With Medetomidine Adulteration: A Multicenter Study From Philadelphia, PA. J Addict Med. 2025 Aug 1. doi: 10.1097/ADM.0000000000001560.
• Durney P, Kahoud JL, Warrick-Stone T, Montesi M, Carter M, Butt S, Mencia AM, Omoregie L, Shah M, Bloomfield M, Tomasko N, Jaffe R, Herens A, Korn WR, Alexander K, Stickle D, Goodstein D, Weinstein LC, London KS. Biochemical Identification and Clinical Description of Medetomidine Exposure in People Who Use Fentanyl in Philadelphia, PA. Int J Mol Sci. 2025 Jul 13;26(14):6715. doi: 10.3390/ijms26146715.
• Kory S. London, Beth Hurwitz, Jennifer Davis, TaReva Warrick-Stone, Alan Cherney, Frederick Randolph, Bernice Bradley-O'Toole, Kate Deis, Karen Alexander, “Are you worried about going into withdrawal today?” Retrospective analysis of single-question, patient-centered screen for substance use and care linkage, The American Journal of Emergency Medicine, Volume 96, 2025, Pages 69-74, ISSN 0735-6757, https://doi.org/10.1016/j.ajem.2025.06.017
• London, K., Sholes, R., Ream, C., Portnoy, A., Walsh, C., Spritzer, K/, Reed, M. (2025). A qualitative evaluation of a hospital-based peer recovery support program. Journal of Substance Use, 1–7. https://doi.org/10.1080/14659891.2025.2512530
• K. London and J.L. Kahoud, A response to: Tranq dope: Characterization of an ED cohort treated with a novel opioid withdrawal. American Journal of Emergency Medicine, https://doi.org/10.1016/j.ajem.2024.11.090
• London K, Li Y, Kahoud JL, Cho D, Mulholland J, Roque S, Stugart L, Gillingham J, Borne E, Slovis B. Tranq Dope: Characterization of an ED cohort treated with a novel opioid withdrawal protocol in the era of fentanyl/xylazine. The American journal of emergency medicine. 2024 Nov 1;85:130-9. https://doi.org/10.1016/j.ajem.2024.08.036
• London K, Matsubara J, Christianson D, Gillingham J, Reed MK (September 12, 2024) Descriptive Analysis of Emergency Department Patients With Substance Use Disorders As Seen by Peer Recovery Specialists in Philadelphia. Cureus 16(9): e69274. https://doi:10.7759/cureus.69274]https://doi:10.7759/cureus.69274
• London K, Les J. Improving Recovery Engagement for Patients with Substance Use Disorder in the Emergency Department. BIOTECHNO 2023.;1567:27-0. ISBN: 978-1-68558-058-2 
• Megan K. Reed, Anne Siegler, Tracy Esteves Camacho, Kory London, Kevin Schaeffer & Kristin L. Rising (2023) Making Harm Reduction More Accessible: Fentanyl Test Strip Awareness and Attitudes among Emergency Department Patients Who Use Drugs, Substance Use & Misuse, https://doi.org/10.1080/10826084.2023.2275561
• Lawson, S., *Hamilton, A., *Lazarus, J., Li, E., Jaffe, G., Weinstein, L., Fiedler, S., & Kelly, E.L. (2025). Evaluation of a multistage implementation of medication for opioid use disorder services in primary care. Substance Use and Misuse, 1-11.
• Kelly, E.L., Hubbard, A. Mauriello, B., Worster, B., & Ashare, R. (2025). The state of the evidence for medical cannabis as a treatment for pain-related sleep impairments: Integrating social determinants of health into research design and policy. Current Sleep Medicine Reports. 11(1), 2-7.
• Reed, M.K., Camacho, T., Gillingham, J., *Gill, S., *Gannon, M., Abetamarco, D., Kelly, E.L., & Weinstein, L.C. (2024). Patient and navigator experiences with the opioid use disorder treatment system in Philadelphia, PA. Journal of Substance Abuse and Treatment, 167, 209509.
• Gannon, M., Short, V., Keith, S., Hand, D., Owen-Oliner, L., Yang, A., Haerizadeh-Yazdi, N., Ize-Iyamu, A., Kelly, E.L., Weinstein, L., Goyal, N., Jeminiwa, R., Abatemarco, D. (2024). Scarce Perinatal Social Support for Women with OUD: Opportunities for Doula Services. Midwifery. 138, 104169.
• *Wallingford, M., Harmon, D., Herens, A., Worster, B., & Kelly, E.L. (2024). The effects of medical cannabis on gastrointestinal symptoms over 12 months. Medical Cannabis and Cannabinoids. 7(1), 80–85.
• *Smith, K.R., *Shah, N.K., Adamczyk A.L., Weinstein, L.C., & Kelly, E.L. (2023). Harm reduction in undergraduate and graduate medical education: A systematic scoping review. BMC Medical Education, 23(1), 1-22.
• *Bui, K., Worster, B., Ryan, J., Pant, S., & Kelly, E.L. (2023). Physician perceptions of their training and practice of certifying patients to use medical cannabis in Pennsylvania. Journal of the American Board of Family Medicine, 36(4), 670-681.
• Hajjar, E., Herens, A., Kelly, E.L., Madden, K., Lungen, J., & Worster, B. (2023). A 12-month observational study of polypharamacy among participants in a state-run medical cannabis program. Biomedicines, 11(1) 158.
• Reed, M.K., Smith, K., *Ciocco, F., Hass, R., Cox, A., Kelly, E.L., & Weinstein, L. (2023). Sorting through life: A mixed methods approach to evaluating patient-important measures of success in a buprenorphine treatment program. Substance Abuse Treatment, Prevention, and Policy, 18(1), 4.
• Kelly, E.L., Reed, M.K., *Schoenauer, K., Smith, K., Hill, S., Scalia-Jackson, K., Li, E., & Weinstein, L.C. (2022). A qualitative examination of the functional, social, and emotional impacts of the COVID-19 pandemic on people who use drugs. International Journal of Environmental Research and Public Health, 19, 9751-9765.
• Ashare, R.L, Kelly, E.L., Hajjar, E.R., Pant, S., Meghani, S., & Worster, B. (2022). Characterizing anxiety, pain, sleep, and quality of life among patients in a state medical marijuana program. Complementary Therapies in Clinical Practice, 48, 101612.
• Reed, M.K., Kelly, E.L., Garber, G., Hajjar, E., Wagner, B., & Worster, B. (2022). A failure to guide: Patient experiences within a state-run cannabis program. Substance Use and Misuse, 57(4), 516-521.
• Worster, B., Smith, K., Ashare, R.L., Hajjar, E., Garber, G., & Wagner, B.A., & Kelly, E.L., (2021). Clinician attitudes, training, and beliefs about cannabis: An interprofessional assessment. Cannabis and Cannabinoid Research, 8(3), 547-556.
• Alexander, K., Pogorzelska-Maziarz, M., Gerolamo, A., Hassen, N., Kelly, E.L., Rising, K. (2021). The impact of COVID-19 on healthcare delivery for people who use opioids: A scoping review. Substance Abuse Treatment, Prevention, and Policy, 16(1), 1-10.
• Kelly, E.L., Pasquarelle, F., Davis, L., Hunt, A., Lee, S., Fairhurst, S., Giambone, L., Murch, L., Thorning, H., Brekke, J.S. (2021). Managing substance use for clients with serious mental illnesses: Knowledge, attitude, and training challenges among outpatient behavioral health providers in California, Ohio, and New York. Journal of Substance Abuse Treatment, 131, 108547
• Lai, S., Li, E., Silverio, A., DeBates, R., Kelly, E.L., & Weinstein, L.C. (2021). “It’s a place that gives me hope”: A qualitative evaluation of a buprenorphine-naloxone group visit program in an urban federally qualified health center. Substance Abuse, 42(4), 858-864.

Sustaining Whole Person Care for People Who Use Drugs: Exploring Alternative Payment Models for Acute Care Admission and Outpatient Bridging Service​

• Funder: Foundation for Opioid Response Efforts​
• PI: Weinstein, Co-I Kelly​

Evaluation of contingency management for Sublocade treatment in Philadelphia             ​

• Funder: Pathways to Housing, PA​
• PI: Kelly, Co-I Weinstein​

Addiction Medicine and Psychiatry Fellowships​

• Funder: Health Resource Services Administration​
• PI : Jangro, Co-I Weinstein​